Anti-inflammatory agents and anti-infectives in combination, corticosteroids and anti-infectives in combination.


  • Tobramycin Sulphate USP equivalent to Tobramycin 0.3% w/v;
  • Dexamethasone Sodium Phosphate USP equivalent to Dexamethasone Phosphate 0.1% w/v;
  • Benzalkonium Chloride Solution BP 0.02% w/v; (Preservative)
  • Sterile aqueous vehicle q.s.

Tamekraz should be used with the following indications:

Prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults and children aged 2 years and older.


One drop instilled into the conjunctival sac(s) every 4 to 6 hours while the patient is awake. During the initial 24 to 48 hours, the dosage may be increased to one drop every two hours while the patient is awake. Dosing should continue for 14 days, not to exceed a maximum of 24 days. Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.

Use in the Elderly:

Clinical studies have indicated dosage modifications are not required for use in the elderly.

Paediatric population:

Tamekraz may be used in children 2 years of age and older at the same dose as in adults. The safety and efficacy in children younger than 2 years of age have not been established, and no data is available. Shake the vial well before use. To prevent contamination of the dropper tip, care should be taken not to touch the eyelids, surrounding areas, or other surfaces with the dropper tip of the vial. Keep
the vial tightly closed when not in use. In case of concomitant therapy with other topical ophthalmic medicinal products, an interval of 5 minutes should be allowed between successive applications.
Eye ointments should be administered last.